Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 885 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GvHD Clear all
Completed No phase listed Observational

Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease

NCT00632658
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
5 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 4, 2026, 1:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Experience of Having Chronic Graft-Versus-Host Disease

NCT00353106
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

NCT00803010
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Tacrolimus (TAC), Methotrexate (MTX), Rapamycin (RAPA)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

NCT02491359
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Carfilzomib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

NCT01309997
View directory record Official record
Conditions
Graft Versus Host Disease, Systemic Scleroderma
Interventions
imatinib mesylate, rituximab
Drug · Biological
Lead sponsor
Lee, Stephanie
Other
Eligibility
2 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Sep 4, 2026, 1:09 PM EDT
Active, not recruiting Phase 2 Interventional

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

NCT04572815
View directory record Official record
Conditions
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab
Drug · Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 4, 2026, 1:09 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 4 Interventional

Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

NCT00574470
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
daclizumab, infliximab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 4, 2026, 1:09 PM EDT
Terminated Phase 2 Interventional Results available

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 4, 2026, 1:09 PM EDT
Recruiting No phase listed Observational

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

NCT03555851
View directory record Official record
Conditions
Leukemia, Not Otherwise Specified, Leukemia, Other
Interventions
Cyclophosphamide, Specimen collection
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

NCT02277639
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
CliniMACs device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 4, 2026, 1:09 PM EDT
Enrolling by invitation Phase 2 Interventional

Chronic Exogenous Ketosis in HFpEF

NCT06937320
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
Interventions
Exogenous Ketone Drink, Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 4, 2026, 1:09 PM EDT
Not listed Phase 3 Interventional

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

NCT02178683
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Tacrolimus and MMF.
Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

NCT03327857
View directory record Official record
Conditions
Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease
Interventions
Neihulizumab (ALTB-168)
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 4, 2026, 1:09 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Brain State-dependent PCMS in Chronic Stroke

NCT04830163
View directory record Official record
Conditions
Stroke
Interventions
Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
Combination Product
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 4, 2026, 1:09 PM EDT
Withdrawn Phase 2 Interventional

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

NCT02174263
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
tocilizumab, laboratory biomarker analysis, quality-of-life assessment
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 4, 2026, 1:09 PM EDT
Recruiting No phase listed Observational

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511
View directory record Official record
Conditions
cGVHD
Interventions
Non-Interventional
Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 4, 2026, 1:09 PM EDT
Recruiting Phase 2 Interventional

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

NCT07315165
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Interventions
Enteral Nutrition
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

NCT00228839
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Infliximab
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 4, 2026, 1:09 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

NCT02999854
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor
Biological · Drug · Procedure
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 4, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional

SynRinse Irrigation Pilot (SIP) Trial

NCT03154541
View directory record Official record
Conditions
Sinusitis, Chronic, Cystic Fibrosis With Other Manifestations
Interventions
Synrinse
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 4, 2026, 1:09 PM EDT
Active, not recruiting Phase 2 Interventional

Itacitinib for the Prevention of Graft Versus Host Disease

NCT04859946
View directory record Official record
Conditions
Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 4, 2026, 1:09 PM EDT